CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 9 enrolled
Drug / intervention
Defactinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01943292
NCT01943292Phase 1Completed
CompareCT.gov

A Phase I Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of VS-6063, a Focal Adhesion Kinase Inhibitor, in Japanese Subjects With Non-Hematologic Malignancies

Verastem, Inc.·interventional·Posted Sep 16, 2013·Updated Mar 9, 2017

In Brief

A Phase 1 clinical trial evaluating Defactinib for Non Hematologic Cancers. Completed, enrolled 9 participants across 1 site.

Detailed Summary

This is a phase I, open-label, dose-escalation trial of defactinib (VS-6063), a focal adhesion kinase inhibitor, in Japanese patients with non-hematologic malignancies. The purpose of this study is to assess the safety (including the recommended phase 2 dose), the pharmacokinetics, and the anti-cancer activity of defactinib (VS-6063).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon Hematologic Cancers
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedSep 16, 2013
Enrollment StartSep 2, 2013
Primary CompletionJun 9, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.8 years ago

Interventions

Defactinibdrug